Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
State-of-the-Art Cancer Biology and Therapeutics in Poland Volume II
share announcement

State-of-the-Art Cancer Biology and Therapeutics in Poland Volume II

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 2586

Special Issue Editors

Dr. Anna Mucha-Małecka

E-Mail Website
Guest Editor
Department of Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, Garncarska 11, 31-115 Cracow, Poland
Interests: molecular biology; radiobiology; immunotherapy; targeted therapy; radiotherapy; head and neck cancers; HPV infections
Special Issues, Collections and Topics in MDPI journals
Dr. Beata Biesaga

E-Mail Website
Guest Editor
Department of Tumor Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, Garncarska 11, 31-115 Cracow, Poland
Interests: cancer

Special Issue Information

Dear Colleagues,

All over the world, including in Poland, there is ongoing progress in the biology and therapy of malignant neoplasms. In 2017, according to the National Cancer Registry, 164,875 new cases of malignant neoplasms were reported in Poland. Thanks to novel treatment methods, cancer is, in many cases, becoming a chronic condition rather than a fatal disease. Contemporary oncology has a wide arsenal of drugs and therapeutic procedures aimed at eradicating neoplastic cells. Modern cancer treatment is based on the concept of an interdisciplinary and holistic approach to cancer therapy. The development of basic sciences in Poland (radiobiology and molecular biology) allows for the identification and verification of new molecular biomarkers.

Cancer biology research has focused on:

  • Searching for genetic factors associated with an increased risk of developing malignant neoplasms;
  • Development of biological prognostic and predictive factors for various types of anticancer treatments;
  • Identification of new targets for immunotherapy and targeted therapies used in cancer patients;
  • The significance of microorganisms (e.g., human papillomavirus) in carcinogenesis and the treatment of cancer patients.

Modern oncohematology with bone marrow transplantation, oncological endocrinology, nuclear medicine, oncological and reconstructive surgery, modern radiotherapy and systemic treatments has also developed. Recent reports on breakthrough therapies and ongoing clinical trials grant patients hope to overcome the disease, with personalized cancer therapy based on the molecular profile of tumors currently developing. The introduction of novel therapies in clinics is associated with new side effects; therefore, it is necessary to optimize molecularly targeted treatments and skillfully manage their toxicity. Due to the improvement of treatment results, it is also necessary to remember supportive management, which is an important element of improving the comfort and quality of life of cancer patients.

I invite you to share your results in the field of biology and treatment of malignant neoplasms in your centers in Poland in this Special Issue of Biomedicine.

Dr. Anna Mucha-Małecka
Dr. Beata Biesaga
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • molecular biology
  • radiobiology
  • immunotherapy
  • targeted therapy
  • radiotherapy
  • multimodal therapy

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

9 pages, 3288 KiB  
Case Report
Stereotactic Radiotherapy in Combination with Immunotherapy in Treatment of Advanced Recurrent Squamous Cell Carcinoma of the Larynx
by Paweł Polanowski, Aleksandra Nasiek, Aleksandra Grządziel, Agnieszka Pietruszka, Krzysztof Składowski and Katarzyna Polanowska
Biomedicines 2023, 11(7), 2067; https://doi.org/10.3390/biomedicines11072067 - 23 Jul 2023
Viewed by 1130
Abstract
Squamous cell carcinoma (SCC) of the larynx in advanced stages is a challenging malignancy to treat with a high recurrence and death rate. An individualized approach to treatment is crucial in such patients. We present a 58-year-old male patient with SCC of the [...] Read more.
Squamous cell carcinoma (SCC) of the larynx in advanced stages is a challenging malignancy to treat with a high recurrence and death rate. An individualized approach to treatment is crucial in such patients. We present a 58-year-old male patient with SCC of the larynx in the T3N0M0 stage who was treated with concurrent radiochemotherapy. A total of 17 months after the radical treatment, the patient underwent a laryngectomy due to recurrence. A total of 11 months after the operation, local failure was diagnosed. In the next order, the patient received six cycles of palliative chemotherapy according to cisplatin 100 mg/m2 and 5-fluorouracil 1000 mg/m2. After three months, due to progression, Nivolumab-based immunotherapy was administered, ensuring disease stabilization. After the 56th cycle of Nivolumab, another progression was documented. The addition of stereotactic radiotherapy (18 Gy in three fractions) to immunotherapy led to significant regression of the disease and enabled the continuation of Nivolumab to the 70th cycle. The presented case demonstrates the usefulness of the combination of stereotactic radiotherapy with immunotherapy in prolonging the local control. Full article
(This article belongs to the Special Issue State-of-the-Art Cancer Biology and Therapeutics in Poland Volume II)
►▼ Show Figures

Figure 1

9 pages, 2203 KiB  
Case Report
Stereotactic Radiotherapy Boost in Treatment of Persistent Periocular Sebaceous Carcinoma after Surgery
by Paweł Polanowski, Aleksandra Nasiek, Aleksandra Grządziel, Ewa Chmielik, Agnieszka Pietruszka, Krzysztof Składowski and Katarzyna Polanowska
Biomedicines 2023, 11(6), 1538; https://doi.org/10.3390/biomedicines11061538 - 26 May 2023
Viewed by 1148
Abstract
Sebaceous carcinoma is a rare malignancy that should be treated with surgical resection. Nonetheless, a dynamic and aggressive course of the disease may disqualify a patient from this treatment. Applying radiotherapy with the escalation dose using a stereotactic boost is worthy of consideration [...] Read more.
Sebaceous carcinoma is a rare malignancy that should be treated with surgical resection. Nonetheless, a dynamic and aggressive course of the disease may disqualify a patient from this treatment. Applying radiotherapy with the escalation dose using a stereotactic boost is worthy of consideration as a radical treatment. In this paper, we present the case study of a young patient with a tumor localized in the periocular area. The patient was treated with operation two times without a satisfactory effect. Conventional radiotherapy, 60 Gy in 30 fractions, combined with chemotherapy based on cisplatin 40 mg/m2 and the addition of a stereotactic radiosurgery boost were administered. The tolerance of this treatment was acceptable. During the 2-year follow-up, local and distant recurrences were not diagnosed. The presented case shows the usefulness of an individualized approach in the radical treatment of sebaceous carcinoma with the use of the stereotactic radiotherapy boost. This is a subsequent example of the implementation of the boost in head and neck carcinoma, which yields a positive result. Full article
(This article belongs to the Special Issue State-of-the-Art Cancer Biology and Therapeutics in Poland Volume II)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop